These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1718 related items for PubMed ID: 27494973

  • 1. [Not Available].
    Mateus C, Libenciuc C, Robert C.
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Nivolumab: A Review in Advanced Melanoma.
    Scott LJ.
    Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
    [Abstract] [Full Text] [Related]

  • 4. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ, Weppler A, Bhave P, Allayous C, Patrinely JR, Ott P, Sandhu S, Haydon A, Lebbe C, Johnson DB, Long GV, Menzies AA, Carlino MS.
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
    [Abstract] [Full Text] [Related]

  • 5. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M.
    Expert Rev Anticancer Ther; 2015 May; 15(9):981-93. PubMed ID: 26313415
    [Abstract] [Full Text] [Related]

  • 6. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
    Kirchberger MC, Ugurel S, Mangana J, Heppt MV, Eigentler TK, Berking C, Schadendorf D, Schuler G, Dummer R, Heinzerling L.
    Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
    [Abstract] [Full Text] [Related]

  • 7. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C.
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [Abstract] [Full Text] [Related]

  • 8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM, Freeman GJ, McDermott DF.
    Clin Ther; 2015 Apr 01; 37(4):764-82. PubMed ID: 25823918
    [Abstract] [Full Text] [Related]

  • 9. The role of nivolumab in melanoma.
    Gomes F, Serra-Bellver P, Lorigan P.
    Future Oncol; 2018 Jun 01; 14(13):1241-1252. PubMed ID: 29328782
    [Abstract] [Full Text] [Related]

  • 10. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.
    Pasquali S, Chiarion-Sileni V, Rossi CR, Mocellin S.
    Cancer Treat Rev; 2017 Mar 01; 54():34-42. PubMed ID: 28189914
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS, Postow M, Lao CD, Schadendorf D.
    Oncologist; 2016 Oct 01; 21(10):1230-1240. PubMed ID: 27401894
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Nivolumab in melanoma.
    Specenier P.
    Expert Rev Anticancer Ther; 2016 Dec 01; 16(12):1247-1261. PubMed ID: 27776441
    [Abstract] [Full Text] [Related]

  • 19. [Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies].
    Robert C, Mateus C.
    Bull Acad Natl Med; 2014 Feb 01; 198(2):297-308. PubMed ID: 26263705
    [Abstract] [Full Text] [Related]

  • 20. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB.
    Pharmacotherapy; 2015 Oct 01; 35(10):963-76. PubMed ID: 26497482
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 86.